PTC Therapeutics Announces Initiation Of Phase 2b Registration-Directed Clinical Trial Of PTC124 In Duchenne/Becker Muscular Dystrophy
PTC Therapeutics, Inc. (PTC), today announced the initiation of an international pivotal trial of PTC124 in patients with Duchenne/Becker muscular dystrophy (DMD/BMD) due to a nonsense mutation. The primary objective of this registration-directed Phase 2b trial is to demonstrate the efficacy of PTC124 as measured by improvements in the walking ability of patients with this progressive genetic disease.
More: continued here
Filed under: Muscular Dystrophy on May 15th, 2008